Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics

Journal of Child and Adolescent Psychopharmacology

Volumn 25, Issue 4, 2015, Pages 351-361

  Rodday, Angie Mae ^a,b   Parsons, Susan K ^a,b   Mankiw, Catherine ^a   Correll, Christoph U ^c   Robb, Adelaide S ^d   Zima, Bonnie T ^e   Saunders, Tully S ^a   Leslie, Laurel K ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; ELECTROLYTE; GLUCOSE; LIPID; NEUROLEPTIC AGENT; PRESCRIPTION DRUG; PROLACTIN; QUETIAPINE; THYROTROPIN; ZIPRASIDONE; GLUCOSE BLOOD LEVEL;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADULT; ARTICLE; BEHAVIOR CHANGE; BLOOD CELL COUNT; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD BEHAVIOR; CHILD PSYCHIATRY; DIET RESTRICTION; DRUG MONITORING; ELECTROCARDIOGRAM; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL SOCIETY; MENTAL PATIENT; METABOLIC SYNDROME X; MIDDLE AGED; PATIENT COMFORT; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT RISK; PHYSICAL EXAMINATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; REFUSAL TO PARTICIPATE; SCHOOL CHILD; SELF REPORT; THYROTROPIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VITAL SIGN; WAIST CIRCUMFERENCE; AGED; ANALYSIS; BLOOD; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHILD; FEMALE; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 84929572479     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2014.0156     Document Type: Article

References (63)

1. Agency for Healthcare Research and Quality: Comparative effectiveness of first and second generation antipsychotics in the pediatric and young adult populations. Rockville, MD:: Agency for Healthcare Research and Quality; 2010.
2. American Academy of Child and Adolescent Psychiatry: Practice parameter for the use of atypical antipsychotic medications in children and adolescents. 2011. Available at https://www.aacap.org/App-Themes/AACAP/docs/practice-parameters/Atypical-Antipsychotic-Medications-Web.pdf. Accessed November 17, 2014.
3. American Board of Medical Specialties: Support for Board Certification and ABMS MOC. 2014, Available at http://www.abms.org/board-certification/support-for-board-certification-and-abms-moc/Accessed on November 15, 2014.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004.
5. Association of American Medical Colleges Center for Workforce Studies: 2012 Physician Specialty Data Book. Available at https://www.aamc.org/download/313228/data/2012physicianspecialtydata book.pdf. Accessed April 7, 2015.
6. Baker DW, Brown T, Buchanan DR, Weil J, Balsley K, Ranalli L, Lee JY, Cameron KA, Ferreira MR, Stephens Q, Goldman SN, Rademaker A, Wolf MS: Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. JAMA Intern Med 174:1235-1241, 2014.
7. Birnbaum ML, Saito E, Gerhard T, Winterstein A, Olfson M, Kane JM, Correll CU: Pharmacoepidemiology of antipsychotic use in youth with ADHD: Trends and clinical implications. Curr Psychiatry Rep 15:382-395, 2013.
8. Blair J, Scahill L, State M, Martin A: Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73-79, 2005.
9. Bobo WV, Cooper WO, Stein CM, Olfson M, Mounsey J, Daugherty J, Ray WA: Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: A Tennessee Medicaid study. BMC Med Res Methodol 12:128, 2012.
10. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
11. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458-1465, 1999.
12. Cook S, Auinger P, Huang TT: Growth curves for cardio-metabolic risk factors in children and adolescents. J Pediatr 155:S6-26, 2009.
13. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008.
14. Correll CU, Kratochvil CJ, March JS: Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 72:655-670, 2011.
15. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
16. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177-206, 2006.
17. Correll CU, Sheridan EM, Del Bello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116-141, 2010.
18. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T: Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 28:w770-w781, 2009.
19. Curtis LH, Masselink LE, Ostbye T, Hutchison S, Dans PE, Wright A, Krishnan RR, Schulman KA: Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 159:362-366, 2005.
20. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564, 2003.
21. Department of Maryland Health and Mental Hygiene: Antipsychotic Review Programs. 2014. Available at https://mmcp. dhmh.maryland.gov/pap/SitePages/Antipsychotics%20Review%20Programs.aspx. Accessed on November 17, 2014.
22. Doey T, Handelman K, Seabrook JA, Steele M: Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 52:363-368, 2007.
23. Findling RL, Kusumakar V, Daneman D, Moshang T, De SG, Binder C: Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362-1369, 2003.
24. Free C, Phillips G, Galli L, Watson L, Felix L, Edwards P, Patel V, Haines A: The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: A systematic review. PLoS Med 10:e1001362, 2013.
25. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E: Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39-47, 2004.
26. Gleason MM, Egger HL, Emslie GJ, Greenhill LL, Kowatch RA, Lieberman AF, Luby JL, Owens J, Scahill LD, Scheeringa MS, Stafford B, Wise B, Zeanah CH: Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry 46:1532-1572, 2007.
27. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA: AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38:1047-1050, 1999.
28. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 166:345-353, 2009.
29. Honey BL, Ramos L, Brahm NC: Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic. J Pediatr Pharmacol Ther 18:292-297, 2013.
30. Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK: Corrected QT Changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials. 54:25-36, 2015.
31. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS: Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 10:CD009582, 2013.
32. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E: Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575-587, 2006.
33. Maayan L, Correll CU: Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517-535, 2011.
34. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B: Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142-1148, 2005.
35. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B: Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32:1037-1042, 2009.
36. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW: Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 164:344-351, 2010.
37. ® 1 2015: Safe and Judicious Antipsychotic Use in Children and Adolescents. 2014. Available at: http://www.ncqa.org/Portals/0/HomePage/Antipsychotics.pdf. Accessed April 7, 2015.
38. Needle JS, Mularski RA, Nguyen T, Fromme EK: Influence of personal preferences for life-sustaining treatment on medical decision making among pediatric intensivists. Crit Care Med 40:2464-2469, 2012.
39. Newcomer JW, Nasrallah HA, Loebel AD: The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24:S1-S6, 2004.
40. Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, Correll CU: Risk of diabetes in children and adolescents exposed to antipsychotics: A nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry 53:971-979, 2014.
41. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006.
42. Olfson M, Blanco C, Wang S, Laje G, Correll CU: National trends in the mental health care of children, adolescents, and adults by officebased physicians. JAMA Psychiatry 71:81-90, 2014.
43. Olfson M, Marcus SC, Weissman MM, Jensen PS: National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521, 2002.
44. Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145-161, 2003.
45. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML: Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12:221-229, 2002.
46. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J: Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 20:218-233, 2011.
47. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343, 2002.
48. Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E: Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9 Suppl 1:I9-19, 2000.
49. Rodday AM, Parsons SK, Correll CU, Robb AS, Zima BT, Saunders TS, Leslie LK: Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics. J Child Adolesc Psychopharmacol 24:90-93, 2014.
50. Rosack J: FDA to require diabetes warning on antipsychotics. Psychiatric News 38:1, 2003.
51. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004.
52. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
53. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Macintyre Ii JC, Pappadopulos E, Greenhill L, Schooler N, Van OK, Jensen PS: Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: A review. J Am Acad Child Adolesc Psychiatry 42:132-144, 2003.
54. Shah BR, Bhattacharyya O, Yu CH, Mamdani MM, Parsons JA, Straus SE, Zwarenstein M: Effect of an educational toolkit on quality of care: A pragmatic cluster randomized trial. PLoS Med 11:e1001588, 2014.
55. Shekelle P, Maglione M, Bagley S, Suttorp M, Mojica WA, Carter J, Rolon C, Hilton L, Zhou A, Chen S, Glassman P: Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Comparative Effectiveness Review No 6 (Prepared by the Southern California/RAND Evidence-based Practice Center under Contract No 290-02-0003). 2007. Available at www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed November 17, 2014.
56. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927-942, 2001.
57. Toren P, Ratner S, Laor N, Weizman A: Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 27:1135-1156, 2004.
58. United States Food and Drug Administration: "Black Box" Warning for Antidepressants. Show #34. FDA Patient Safety News. 2004. Available at http://www.accessdata.fda.gov/psn/transcript.cfm?show = 34. Accessed on January 5, 2012
59. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19:629-635, 2009.
60. Walter G, DeLaroche A, Soh N, Hunt G, Cleary M, Malhi G, Lambert T, Correll C, Rey J: Side effects of second-generation antipsychotics: The experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry 16:253-262, 2008.
61. Yip L, Dart RC, Graham K: Olanzapine toxicity in a toddler. Pediatrics 102:1494, 1998.
62. Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, Dubowski M, Mendez-Lewis M: Psychotropic medication patterns among youth in foster care. Pediatrics 121:e157-e163, 2008.
63. Zuddas A, Zanni R, Usala T: Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600-620, 2011.